Introduction
Asthma is one of the most common chronic respiratory diseases, affecting more than 300 million people worldwide [2] and approximately 5.4 million in the UK [3] . The clinical symptoms and airway obstruction that characterize asthma fluctuate widely over time and range from mild to profoundly disabling [4] . Acute exacerbations of asthma impose considerable morbidity on patients and constitute a major burden on healthcare resources [4] . Their unpredictable nature can impact patients' psychological well-being, particularly in causing feelings of anxiety and loss of control, and worsen patients' quality of life (QoL) [5] [6] [7] [8] .
The main goal of asthma treatment is to achieve asthma control and minimize the risk of exacerbations and side effects [4] ; consequently, the main clinical focus tends to be on symptoms management. However, patients are often more concerned with how their symptoms make them feel and the impact that symptoms have on their everyday lives [8] .
Therefore, as well as improving objective clinical outcomes, therapeutic interventions for asthma should also aim to improve patients' health-related-QoL (HR-QoL) [9] .
In recent years, health care has moved towards a patient-centric approach, which considers patients' perspectives regarding the impact of disease and its treatment. Patientreported outcomes (PROs) are now widely used in clinical practice, and in clinical trials, to capture patients' subjective perceptions of changes in health status (symptoms or function) and HR-QoL that occur as a result of treatment intervention [10] [11] [12] . PROs are measures of health status directly elicited from patients, without external interpretation, and usually take the form of short, self-completed questionnaires. Numerous PRO instruments have been developed for use in patients with asthma, but not all are validated [12] . Including PRO endpoints in asthma clinical trials can complement more traditional efficacy endpoints, such as lung function, and provide a more comprehensive picture of the response to treatment.
However, a review of recently published asthma clinical trials found that fewer than 10% had included PRO evaluations and none had been conducted in a real-world setting [13] .
Effectiveness studies are often favored over traditional double-blind, randomized controlled trials (RCTs) for conducting comprehensive PRO assessments to determine the real-world impact of treatment, because they more closely reflect routine clinical care [11] .
The Salford Lung Study in asthma (SLS asthma), a 12-month, open-label RCT conducted in UK primary care, compared the effectiveness and safety of initiating fluticasone furoate/vilanterol (FF/VI) versus continuing usual care (UC) in patients with symptomatic asthma. The trial incorporated a number of PRO effectiveness endpoints and topline PRO data have been published previously [1] . Here, we expand on the primary analysis of SLS asthma, reporting additional PRO findings from the study to provide a comprehensive picture of the impact of initiating FF/VI versus continuing UC in the overall patient population, and in patient subsets defined by asthma maintenance therapy at baseline. In particular, we aim to provide new, more detailed information on the impact of treatment on the components (i.e. domains/individual items) of the various PROs included in the study and on the likelihood of patients maintaining or improving asthma control during the study period.
Methods

Study design and patients
The SLS asthma study design has been described previously [1] . Briefly, this The SLS asthma study was designed to mimic routine clinical practice, with minimal disruption to patients' everyday lives, and treatment modifications were permitted at GPs' discretion throughout the study in both treatment groups. There were few protocol-mandated clinic visits (screening, randomization and 12 months/early withdrawal visit only) and data were collected continuously and remotely via patients' electronic health records using an integrated primary and secondary care-linked database system. 
PRO questionnaires Asthma Control Test
The ACT is a validated, self-administered questionnaire, including for use over the telephone [14] . It comprises 5 questions that assess asthma control during the past 4 weeks on a 5-point categorical scale with the total score calculated as the sum of the scores from all 5 questions (range 5-25) [15] . Questions evaluate the effect of asthma on daily functioning, frequency of shortness of breath, frequency of asthma symptoms leading to night-time awakenings, frequency of rescue medication use, and overall self-assessment of asthma control. A higher total ACT score indicates better asthma control: 'well controlled', ≥ 20 points; 'partially controlled', 16-19 points; 'uncontrolled', ≤ 15 points. The minimally important difference (MID) for ACT is 3 points [16] . The ACT was completed at baseline (randomization) and at Weeks 12, 24, 40, and 52/early withdrawal visit. Patients completed the questionnaire electronically at baseline and the Week 52/early withdrawal visit (as these were the protocol-mandated study visits), and over the telephone at Weeks 12, 24, 40 (questionnaire conducted remotely so as to preserve the real-world nature of the trial).
Standardised Asthma Quality of Life Questionnaire
The Standardised Asthma Quality of Life Questionnaire (AQLQ [S]), a modified version of the original AQLQ, is a validated, disease-specific, self-administered questionnaire [17, 18] designed to evaluate the impact of asthma treatment on patients' QoL over the past 2 weeks. The AQLQ (S) comprises 32 items in 4 domains (activity limitation 
Work Productivity and Activity Impairment: asthma
The Work Productivity and Activity Impairment (WPAI): asthma questionnaire is a validated, self-administered, 6-item questionnaire [20, 21] designed to quantitatively assess patients' overall work impairment and overall activity impairment due to asthma during the past 7 days. Four types of asthma-derived scores are calculated: absenteeism (work time missed); presenteeism (impairment at work/reduced on-the-job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism) and activity impairment. The WPAI: asthma questionnaire was completed electronically at baseline and at the Week 52/early withdrawal visit.
EuroQol 5-Dimensions 3-Levels questionnaire
The EuroQol 5-Dimensions 3-Levels questionnaire (EQ-5D-3L) is a standardized, self-administered instrument used to provide a simple, generic measure of patients' health status "today" [22] . The questionnaire comprises 2 parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system covers 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each measured on a 3-point Likert scale (1 = no problems, 2 = some problems, and 3 = extreme problems). Based on patients' selection of levels that reflect their "own health state today" for each of the 5 dimensions, 1 of 243 distinct health states can be assigned and a single utility score calculated, ranging from 0-1. A higher utility score is indicative of better QoL. For the EQ VAS, patients rate their current health status by selecting a score on a continuous vertical visual scale ranging from 0 = worst imaginable health state to 100 = best imaginable health state. The EQ-5D-3L questionnaire was completed electronically at baseline and at the Week 52/early withdrawal visit. 
Study endpoints
Statistical analyses Analysis populations
All analyses were conducted according to the intention-to-treat (ITT) principle. The overall study population included all randomized patients who received at least 1 prescription of study medication (FF/VI or UC). The primary effectiveness analysis (PEA) population included all patients in the overall study population with a baseline ACT score of < 20.
Subsets of the overall and PEA populations defined by baseline intended asthma maintenance therapy (ICS or ICS/LABA) were also analyzed; these included patients whose asthma maintenance therapy at baseline per randomization stratification and whose prerandomization prescription was either ICS alone or ICS/LABA (fixed dose combination or in separate inhalers).
PRO analyses
The percentage of ACT responders based on the composite primary endpoint at Week 24 was analyzed in the overall PEA population and corresponding ICS and ICS/LABA subsets. A supporting analysis in the overall study population was also conducted. The percentage of patients achieving either the threshold of ≥ 20 points for 'well controlled' asthma or achieving the MID for ACT of ≥ 3 points at Week 24 were determined separately for each population. Statistical analyses were conducted using logistic regression.
ACT transitional probabilities were analyzed in the overall study population and corresponding ICS and ICS/LABA subsets. A PEA sensitivity analysis was also conducted.
Using a Markov chain method, the probabilities of patients transitioning from one state of asthma control to another based on ACT score at a given time point were determined for the FF/VI and UC treatment groups (e.g., the probability of patients transitioning from an uncontrolled state to a partially controlled state or a well-controlled state, etc). Probabilities were calculated using an ordinal logistic regression model [23]; summary statistics were descriptive only. AQLQ (S) responder analyses at Week 52 were performed in the overall study population and corresponding ICS and ICS/LABA subsets using logistic regression. Mean change from baseline in WPAI: asthma-derived scores at Week 52 were analyzed in the overall study population and corresponding ICS and ICS/LABA subsets. Statistical analyses were performed using analysis of covariance (ANCOVA). EQ-5D-3L analyses were performed in the overall study population and corresponding ICS and ICS/LABA subsets.
The percentage of responders (patients self-scoring 1 = no problems) for each of the 5 descriptive domains was calculated for FF/VI and UC and between-group differences were analyzed using logistic regression. Least squares (LS) mean change from baseline to Week 52 in EQ-5D-3L utility and EQ VAS scores were also calculated, and between-group differences were determined using ANCOVA.
Results
Patients
In total, 4233 patients (2114 FF/VI; 2119 UC) were included in the overall study population. Patient demographics and baseline characteristics have been reported previously; these were well matched between the treatment groups [1] . Briefly, patients had a mean (standard deviation [SD]) age of 50 (16) years and 59% were female. Mean (SD) body mass index was 30 (7) kg/m 2 and 53% were current or former smokers. Most patients (87%) had been diagnosed with asthma at least 5 years previously; 90% experienced daytime symptoms at least twice weekly and 36% had experienced at least 1 exacerbation in the year before randomization. In total, 3026 (71%) patients in the overall study population had a baseline ACT score < 20 and were included in the PEA population (1512 FF/VI; 1514 UC). ACT composite analysis (Table 1) . Findings were also consistent in the overall study population (data not shown).
ACT -Individual questions
Table 1
Contribution of ACT total score ≥ 20 and improvement from baseline ≥ 3 to the composite primary effectiveness endpoint in SLS asthma (Week 24 data; PEA population).
Patients, n/N (%) b ORs and 95% CIs for the difference between FF/VI and UC were determined using a logistic regression model adjusted for randomized treatment, baseline ACT total score, baseline ACT total score squared (composite endpoint only), asthma maintenance therapy at baseline per randomization stratification, age, and gender.
c For analysis of the ICS and ICS/LABA subsets of the PEA population, the statistical models did not include the asthma maintenance therapy at baseline per randomization stratification variable.
Abbreviations: ACT, Asthma Control Test; CI, confidence interval; FF/VI, fluticasone furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; OR, odds ratio; PEA, primary effectiveness analysis; SLS, Salford Lung Study; UC, usual care.
improved their asthma control during the study, regardless of control status at baseline (Fig.   1, A) . Similar findings were observed in the ICS and ICS/LABA subsets (Fig. 1, B, C) .
Conversely, patients continuing on UC were more likely to have worsening of asthma control Fig. 1 ) or to remain uncontrolled or partially controlled ( Supplementary   Fig. 2 ). Results were consistent in the PEA population (data not shown). Many patients showed improved asthma control early on in the trial, with the most prominent effect seen during the baseline to 12 weeks interval followed by a trend of stabilization thereafter (Supplementary Table 2 ; overall study population). Similar findings were observed in the ICS and ICS/LABA subsets of the overall study population (Supplementary   Tables 3 and 4 ) and in the PEA population (data not shown). 
(Supplementary
AQLQ (S) analyses
WPAI: asthma-derived scores
In the overall study population, mean baseline WPAI scores for FF/VI and UC, Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; FF/VI, fluticasone furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LS, least squares; SE, standard error; UC, usual care; WPAI, work productivity and activity impairment.
EQ-5D-3L health status
At baseline, the proportions of responders for each of the 5 EQ-5D-3L descriptive dimensions appeared similar between the FF/VI and UC groups in the overall study population ( Table 3 c ORs, 95% CIs, and p-values were calculated using a logistic regression model adjusted for randomized treatment, asthma maintenance therapy at baseline per randomization stratification, ACT total score at baseline per randomization stratification, gender, age, and the relevant baseline EQ-5D-3L domain score.
Abbreviations: CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire; FF/VI, fluticasone furoate/vilanterol; OR, odds ratio; UC, usual care.
In the overall study population, the LS mean change in EQ-5D-3L utility score from baseline to Week 52 was 0.0170 for FF/VI and 0.0051 for UC; the between-group difference was not statistically significant (difference: 0.0119 [95% CI: -0.0017 to 0.0254]; p = .086) ( Table 4 ).
The LS mean change from baseline to Week 52 in EQ VAS score was 3.0 for FF/VI and 1.4
for UC, with a statistically significant difference between the groups (difference 1.6 [95% CI: (Table 4) . Table 4 Statistical analysis of change from baseline in EQ-5D-3L utility and VAS scores (Week 52 data a b Between-group differences (FF/VI versus UC), 95% CIs, and p-values were calculated using an ANCOVA model adjusted for randomized treatment, asthma maintenance therapy at baseline per randomization stratification, ACT total score at baseline per randomization stratification, gender, age, and baseline EQ-5D-3L utility/VAS score (as appropriate).
0.4-2.7]; p = .007). A similar treatment effect with FF/VI versus UC was also observed in the ICS and ICS/LABA subsets
c For analysis of the ICS and ICS/LABA subsets of the overall study population, the statistical models did not include the asthma maintenance therapy at baseline per randomization stratification variable.
Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire; EQ VAS, EuroQol visual analogue scale; FF/VI, fluticasone furoate/vilanterol; LS, least squares; SE, standard error; UC, usual care.
Discussion
In this detailed analysis of prospectively collected PRO data from the SLS asthma study, we aimed to provide a fuller picture of the impact of initiating FF/VI versus continuing UC on asthma patients' HR-QoL, and also to explore the impact of patients' baseline asthma maintenance therapy (ICS or ICS/LABA) on PRO findings. The present work expands on the primary results of the SLS asthma study [1] , demonstrating that the observed improvement In addition to the asthma-specific PRO tools used in the SLS asthma study, patients' perceptions of generic health status were also recorded using EQ-5D-3L. At Week 52, the odds of patients being EQ-5D-3L responders were statistically significantly higher with initiating FF/VI versus continuing UC for 3 of the 5 descriptive domains (mobility, usual activities, and pain/discomfort); however, this did not translate into a significantly greater change from baseline to Week 52 in overall EQ-5D-3L utility scores with FF/VI versus UC. In contrast, patients initiating FF/VI had a statistically significantly greater improvement from baseline to Week 52 in EQ VAS score.
The results for all evaluated PRO endpoints in the overall/PEA populations were consistent across the ICS and ICS/LABA subsets, supporting the benefit of FF/VI over UC regardless of patients' baseline maintenance therapy. As baseline therapy is likely indicative of baseline asthma severity/degree of asthma control (with addition of LABA to ICS recommended as an option for patients whose asthma is uncontrolled on ICS alone [4] ), the consistency of findings in these subsets suggests that the patient-perceived benefits of initiating FF/VI versus continuing UC may be relevant across different severities of disease, and also suggest that the results were not mediated by a step-up in treatment from ICS to ICS/LABA as part of the study design.
Although the SLS asthma study demonstrated improved asthma control (based on ACT) with initiation of FF/VI versus continuing UC, there was no observed between-group difference in asthma exacerbation rates in the overall SLS population [1] . It could be hypothesized, therefore, that the observed effects of FF/VI versus UC on PROs in the present study are not due to a reduction in exacerbations but instead due to an "everyday" effect on asthma control. In support of this, the PRO questionnaires utilized in this study recorded a range of outcomes (including asthma symptoms, impairment of function/activities of daily living, ability to work, and overall health status) and we observed a consistent treatment effect with FF/VI versus UC across the different domains/items of the various questionnaires. It was not possible, however, to pinpoint individual elements that may have been responsible for the observed results or that were predictive of positive outcomes; this may be of interest to explore in future studies. 
Conclusions
Overall, our findings suggest that initiating treatment with once-daily inhaled FF/VI provides not only better asthma control compared with continuing UC in patients with symptomatic asthma, but also results in consistent improvements in HR-QoL as perceived by patients, which are highly relevant factors for guiding asthma treatment. Furthermore, the observed effects of initiating FF/VI versus continuing UC on asthma control were shown to be consistent regardless of patients' initial asthma control status. 
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Supplementary Table 4
Transitional probability of asthma control status (based on ACT scores) in a recorded visit according to control status in the previous visit (ICS/LABA subset of overall study population;
FF/VI n = 1325; UC n = 1325). a Responders were defined as patients who self-scored 1 = no problems for a given dimension.
b Data based on last available on-treatment measurement (Week 52 or early withdrawal visit).
c ORs, 95% CIs, and p-values were calculated using a logistic regression model adjusted for randomized treatment, ACT total score at baseline per randomization stratification, gender, age, and the relevant baseline EQ-5D-3L domain score.
